CA2890642C - Method for the preparation of human albumin with reduced level of dissolved oxygen - Google Patents

Method for the preparation of human albumin with reduced level of dissolved oxygen Download PDF

Info

Publication number
CA2890642C
CA2890642C CA2890642A CA2890642A CA2890642C CA 2890642 C CA2890642 C CA 2890642C CA 2890642 A CA2890642 A CA 2890642A CA 2890642 A CA2890642 A CA 2890642A CA 2890642 C CA2890642 C CA 2890642C
Authority
CA
Canada
Prior art keywords
albumin
solution
stage
dissolved oxygen
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2890642A
Other languages
English (en)
French (fr)
Other versions
CA2890642A1 (en
Inventor
Juan Ignacio Jorquera Nieto
Ana Maria Ortiz Fernandez
Montserrat Costa Rierola
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grifols SA
Original Assignee
Grifols SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52003454&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2890642(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grifols SA filed Critical Grifols SA
Publication of CA2890642A1 publication Critical patent/CA2890642A1/en
Application granted granted Critical
Publication of CA2890642C publication Critical patent/CA2890642C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2890642A 2014-05-29 2015-05-01 Method for the preparation of human albumin with reduced level of dissolved oxygen Active CA2890642C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201430824A ES2524516B1 (es) 2014-05-29 2014-05-29 Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
ES201430824 2014-05-29

Publications (2)

Publication Number Publication Date
CA2890642A1 CA2890642A1 (en) 2015-11-29
CA2890642C true CA2890642C (en) 2019-02-12

Family

ID=52003454

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2890642A Active CA2890642C (en) 2014-05-29 2015-05-01 Method for the preparation of human albumin with reduced level of dissolved oxygen

Country Status (22)

Country Link
US (1) US10350274B2 (enExample)
EP (1) EP2952203B9 (enExample)
JP (3) JP2015224251A (enExample)
KR (1) KR101960729B1 (enExample)
CN (1) CN105315362B (enExample)
AR (1) AR100618A1 (enExample)
AU (1) AU2015202413B2 (enExample)
BR (1) BR102015012091A8 (enExample)
CA (1) CA2890642C (enExample)
CL (1) CL2015001446A1 (enExample)
ES (2) ES2524516B1 (enExample)
HU (1) HUE031823T2 (enExample)
IL (1) IL238898B (enExample)
MX (1) MX362869B (enExample)
MY (1) MY171771A (enExample)
NZ (1) NZ708537A (enExample)
PL (1) PL2952203T3 (enExample)
PT (1) PT2952203T (enExample)
RU (1) RU2657578C2 (enExample)
SG (1) SG10201504137PA (enExample)
TW (1) TWI607018B (enExample)
ZA (1) ZA201503539B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2524516B1 (es) * 2014-05-29 2015-03-31 Grifols Worldwide Operations Limited Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
EP3426265B1 (en) 2016-04-28 2021-09-22 Alkahest, Inc. Plasma fractions as therapy for tumor growth and progression
IL304946A (en) 2016-08-18 2023-10-01 Alkahest Inc Blood plasma fractions as a treatment for cognitive disorders associated with aging
BR112019022402A2 (pt) 2017-04-26 2020-05-19 Alkahest Inc regime de dosagem para tratamento de comprometimentos cognitivo e motor com plasma sanguíneo e produtos de plasma sanguíneo
WO2020018343A1 (en) 2018-07-20 2020-01-23 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
MX2021004755A (es) 2018-10-26 2021-06-08 Alkahest Inc Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria.
CN109627322A (zh) * 2019-01-07 2019-04-16 中国科学院过程工程研究所 一种从Cohn组分Ⅴ上清中分离纯化人血清白蛋白的方法
WO2021091855A1 (en) 2019-11-04 2021-05-14 Alkahest, Inc. Blood plasma fractions for use in muscle regeneration
US11660316B2 (en) 2019-11-20 2023-05-30 Alkahest, Inc. Methods of inducing liver regeneration by administering a plasma protein fraction
JP2026511640A (ja) 2023-03-29 2026-04-14 グリフォルス・ワールドワイド・オペレーションズ・リミテッド ＦｃεＲＩβ自己抗体のレベルが低減された血漿製剤の組成物および調製方法
CN118166053B (zh) * 2024-03-15 2025-02-07 通化安睿特生物制药股份有限公司 一种制备低o-糖基化水平的重组人白蛋白的方法
WO2025230830A1 (en) 2024-04-29 2025-11-06 Alkahest, Inc. Compositions of blood plasma fractions and their use in treatment of spinal muscular atrophy (sma)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4094965A (en) * 1977-04-01 1978-06-13 New England Nuclear Corporation Diagnostic agents containing albumin and method for making same
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
JPH07126182A (ja) * 1993-10-27 1995-05-16 Green Cross Corp:The 組換えヒト血清アルブミン製剤の滅菌方法
SE9402119D0 (sv) * 1994-06-16 1994-06-16 Pharmacia Ab Solution
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
JP4254117B2 (ja) * 2001-03-27 2009-04-15 ニプロ株式会社 アルブミン溶液収容プラスチック容器
EP1245217B1 (en) * 2001-03-27 2009-10-28 Nipro Corporation Plastic container containing albumin solution
JP4225416B2 (ja) * 2001-06-29 2009-02-18 旭化成ファーマ株式会社 タンパク質製剤の安定性を改善する方法
US7252799B2 (en) * 2001-08-31 2007-08-07 Clearant, Inc. Methods for sterilizing preparations containing albumin
ES2270245T3 (es) * 2003-08-28 2007-04-01 Nipro Corporation Vehiculo de oxigeno artificial y su metodo de produccion.
ES2391657T3 (es) * 2006-02-07 2012-11-28 Shire Human Genetic Therapies, Inc. Composiciones estabilizadas de proteínas que tienen un resto tiol libre
ES2294976B1 (es) * 2007-11-12 2008-12-16 Grifols, S.A. "procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion".
JP5990880B2 (ja) * 2011-08-31 2016-09-14 東レ株式会社 有用タンパク質組成物およびその製造方法
CN102816230B (zh) * 2012-08-27 2014-02-12 同路生物制药股份有限公司 人血白蛋白的制备方法
ES2524516B1 (es) * 2014-05-29 2015-03-31 Grifols Worldwide Operations Limited Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido

Also Published As

Publication number Publication date
JP2015224251A (ja) 2015-12-14
ES2524516A1 (es) 2014-12-09
SG10201504137PA (en) 2015-12-30
CA2890642A1 (en) 2015-11-29
BR102015012091A2 (pt) 2016-01-05
US20170000855A9 (en) 2017-01-05
BR102015012091A8 (pt) 2021-03-16
TW201544510A (zh) 2015-12-01
AU2015202413A1 (en) 2015-12-17
PL2952203T3 (pl) 2017-02-28
MY171771A (en) 2019-10-29
PT2952203T (pt) 2016-11-23
EP2952203B9 (en) 2018-03-14
CL2015001446A1 (es) 2016-05-13
ES2524516B1 (es) 2015-03-31
EP2952203B1 (en) 2016-10-26
ZA201503539B (en) 2017-01-25
MX2015006407A (es) 2015-11-30
AU2015202413B2 (en) 2017-08-31
CN105315362B (zh) 2019-10-25
RU2015118453A (ru) 2016-12-10
US20150343025A1 (en) 2015-12-03
TWI607018B (zh) 2017-12-01
KR20160024348A (ko) 2016-03-04
ES2601137T3 (es) 2017-02-14
EP2952203A1 (en) 2015-12-09
JP2018115210A (ja) 2018-07-26
IL238898B (en) 2018-01-31
HUE031823T2 (en) 2017-08-28
NZ708537A (en) 2017-06-30
JP2020111614A (ja) 2020-07-27
KR101960729B1 (ko) 2019-03-21
MX362869B (es) 2019-02-20
CN105315362A (zh) 2016-02-10
AR100618A1 (es) 2016-10-19
US10350274B2 (en) 2019-07-16
RU2657578C2 (ru) 2018-06-14

Similar Documents

Publication Publication Date Title
AU2015202413B2 (en) Method for the preparation of human albumin with reduced level of dissolved oxygen
JP5744959B2 (ja) 解毒療法に使用するためのヒトアルブミンを高効率で得る方法
CN118203658A (zh) 一种重组抗Claudin18.2全人源单克隆抗体注射液制剂及制备方法
KR100839937B1 (ko) 가열처리 공정을 포함하는 인체 혈청알부민의 제조방법
Tanabe et al. Denatured human α-defensin attenuates the bactericidal activity and the stability against enzymatic digestion
ES2261487T3 (es) Metodo de monomerizacion de polimeros de albumina de suero humano.
JP3291340B2 (ja) 非グリコシル化還元型組換えヒトｉｌ２の安定化医薬組成物及びその製造方法
US20180250368A1 (en) Liquid composition of human albumin for therapeutic use
JP4798831B2 (ja) ヒト血清アルブミンのミスホールディングを抑制する方法
Bozhinov et al. Evidence for the presence of glycation adducts in protein therapeutics
EP4431520A1 (en) Method for the preparation of thiol-enriched albumin and uses related thereto and thereof
Ebrahim-Damavandi et al. Reducing allergenicity of bovine beta lactoglobulin throughout Cu complexes
Vahidzadeh et al. Studies on the interaction of colchicine and human serum albumin by the measurement of zeta-potential
BR112020001363A2 (pt) formulações de hemopexina
Lang et al. Chemical characterization of human urine albumin in proteinuria
Jayat et al. Design of Beta-Lactoglobulins with Increased Affinities for Retinol and Palmitic Acid

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20161104

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250403

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250403